NASDAQ:HZNP Horizon Therapeutics Public (HZNP) Stock Price, News & Analysis → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Free HZNP Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$116.30▼$116.3050-Day Range$112.60▼$116.3052-Week Range$60.03▼$116.38VolumeN/AAverage Volume2.50 million shsMarket Capitalization$26.63 billionP/E Ratio62.19Dividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Horizon Therapeutics Public alerts: Email Address Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. About Horizon Therapeutics Public Stock (NASDAQ:HZNP)Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.Read More Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. HZNP Stock News HeadlinesDecember 21, 2023 | seekingalpha.com5 Biotech Acquisition Targets To Accumulate In 2024November 16, 2023 | msn.comNasdaq On Horizon For Psyence Group: Psilocybin Therapeutics Division Forms New Business CombinationApril 26, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. October 24, 2023 | chicago.suntimes.comHorizon Therapeutics cut jobs in Deerfield after Amgen acquisitionOctober 24, 2023 | msn.com350 Horizon Therapeutics workers to be laid off, mostly from Deerfield offices, following acquisition by AmgenOctober 6, 2023 | finance.yahoo.comRule 17(e) Announcement - Horizon Therapeutics plcOctober 5, 2023 | stocknews.com3 Pharma Stocks With Potential to Outperform Pfizer Inc. (PFE) in OctoberOctober 5, 2023 | stockhouse.comRule 17(d) Announcement - Horizon Therapeutics plcApril 26, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. October 5, 2023 | finance.yahoo.comRule 17(d) Announcement – Horizon Therapeutics plcOctober 2, 2023 | finance.yahoo.comHorizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2023September 26, 2023 | benzinga.comBoard Member at Horizon Therapeutics Exercises Options Worth $2.31MSeptember 26, 2023 | finance.yahoo.comHorizon Therapeutics plc Named to U.S. News & World Report’s 2024 List of Best Companies to Work For in the Health Care IndustrySeptember 19, 2023 | finance.yahoo.comHorizon Therapeutics plc Ranks Number One on the Fortune Best Workplaces in Biopharma 2023 ListSeptember 19, 2023 | finance.yahoo.comHealth care: FTC Chair Lina Khan to crack down on 'below radar' dealsSeptember 13, 2023 | finance.yahoo.comQ32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia AreataSeptember 5, 2023 | finance.yahoo.comHorizon Therapeutics Announces Date of Irish Court Hearing to Sanction Scheme of ArrangementSeptember 4, 2023 | benzinga.comHere's How Much $1000 Invested In Horizon Therapeutics 10 Years Ago Would Be Worth TodaySeptember 1, 2023 | finanznachrichten.deHorizon Therapeutics plc and Amgen: Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close AcquisitionAugust 28, 2023 | finance.yahoo.comFTC suspends challenge to Amgen-Horizon Therapeutics dealAugust 26, 2023 | reuters.comUS FTC suspends challenge to block Amgen's $27.8 bln deal for Horizon TherapeuticsAugust 23, 2023 | finance.yahoo.comHorizon Therapeutics plc Ranks First in Overall Corporate Reputation by Rare Disease Patient Advocacy GroupsAugust 16, 2023 | seekingalpha.comHorizon Therapeutics: Can Investors Profit From Amgen Deal Confusion?August 16, 2023 | seekingalpha.comImproved Outlook For Horizon Therapeutics And AmgenAugust 9, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Horizon Therapeutics (HZNP) and Biogen (BIIB)August 9, 2023 | markets.businessinsider.comHorizon Therapeutics (HZNP) Receives a Hold from H.C. WainwrightAugust 8, 2023 | finance.yahoo.comHorizon Therapeutics plc Reports Second-Quarter 2023 Financial ResultsSee More Headlines Receive HZNP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Horizon Therapeutics Public and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2023Today4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:HZNP CUSIP44047T10 CIK1492426 Webwww.horizontherapeutics.com Phone(531) 772-2100Fax224-383-3001Employees2,115Year Founded2008Profitability EPS (Most Recent Fiscal Year)$1.87 Trailing P/E Ratio62.19 Forward P/E Ratio27.76 P/E Growth3.96Net Income$521.48 million Net Margins12.02% Pretax Margin12.18% Return on Equity20.46% Return on Assets11.52% Debt Debt-to-Equity Ratio0.48 Current Ratio4.27 Quick Ratio4.09 Sales & Book Value Annual Sales$3.63 billion Price / Sales7.34 Cash Flow$7.05 per share Price / Cash Flow16.49 Book Value$22.38 per share Price / Book5.20Miscellaneous Outstanding Shares228,990,000Free Float223,957,000Market Cap$26.63 billion OptionableOptionable Beta1.03 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Timothy P. Walbert (Age 56)Chairman, Pres & CEO Comp: $3.5MMr. Aaron L. Cox (Age 40)Exec. VP of Fin. & CFO Comp: $1.36MMr. Sean M. Clayton J.D. (Age 44)Exec. VP & Gen. Counsel Comp: $7.03MMr. Andy Pasternak (Age 52)Exec. VP & Chief Strategy Officer Comp: $1.4MDr. Elizabeth H.Z. Thompson Ph.D. (Age 48)Exec. VP of R&D Comp: $3.66MMr. Patrick McIlvenny (Age 44)Sr. VP & Chief Accounting Officer Ms. Tina E. VenturaSr. VP & Chief Investor Relations OfficerMr. Geoffrey M. Curtis (Age 48)Exec. VP of Corp. Affairs & Chief Communications Officer Ms. Keli WalbertExec. VP & Chief Marketing OfficerMs. Jane GonnermanSr. VP of Corp. Devel. & Chief of Staff, Office of the CEOMore ExecutivesKey CompetitorsRoyalty PharmaNASDAQ:RPRXAlexion PharmaceuticalsNASDAQ:ALXNMyoKardiaNASDAQ:MYOKJazz PharmaceuticalsNASDAQ:JAZZElanco Animal HealthNYSE:ELANView All CompetitorsInstitutional OwnershipNomura Holdings Inc.Sold 890,700 shares on 3/27/2024Ownership: 0.000%Bardin Hill Management Partners LPSold 1,767 shares on 2/14/2024Ownership: 0.000%PSquared Asset Management AGSold 6,020 shares on 2/14/2024Ownership: 0.000%P Schoenfeld Asset Management LPSold 1,612,400 shares on 2/14/2024Ownership: 0.000%Highbridge Capital Management LLCSold 1,500 shares on 2/12/2024Ownership: 0.000%View All Institutional Transactions HZNP Stock Analysis - Frequently Asked Questions Should I buy or sell Horizon Therapeutics Public stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics Public in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" HZNP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HZNP, but not buy additional shares or sell existing shares. View HZNP analyst ratings or view top-rated stocks. How were Horizon Therapeutics Public's earnings last quarter? Horizon Therapeutics Public Limited (NASDAQ:HZNP) released its earnings results on Tuesday, August, 8th. The biopharmaceutical company reported $1.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.08. The biopharmaceutical company earned $945 million during the quarter, compared to analyst estimates of $873.52 million. Horizon Therapeutics Public had a trailing twelve-month return on equity of 20.46% and a net margin of 12.02%. Horizon Therapeutics Public's revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.07 earnings per share. What is Timothy Walbert's approval rating as Horizon Therapeutics Public's CEO? 70 employees have rated Horizon Therapeutics Public Chief Executive Officer Timothy Walbert on Glassdoor.com. Timothy Walbert has an approval rating of 73% among the company's employees. What other stocks do shareholders of Horizon Therapeutics Public own? Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics Public investors own include Alibaba Group (BABA), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), Netflix (NFLX), Gilead Sciences (GILD), Tesla (TSLA), AbbVie (ABBV), Micron Technology (MU) and PayPal (PYPL). Does Horizon Therapeutics Public have any subsidiaries? The following companies are subsidiares of Horizon Therapeutics Public: Curzion Pharmaceuticals Inc., HZNP Canada Limited, HZNP Finance Limited, HZNP Limited, Horizon Medicines LLC, Horizon Ophthalmology Inc, Horizon Orphan Holdings LLC, Horizon Orphan LLC, Horizon Pharma Israel Holding Corp. Ltd, Horizon Therapeutics Capital Limited, Horizon Therapeutics Finance Limited, Horizon Therapeutics Finance S.à.r.l, Horizon Therapeutics GmbH, Horizon Therapeutics Holdings Limited, Horizon Therapeutics Investment Limited, Horizon Therapeutics Ireland DAC, Horizon Therapeutics LLC, Horizon Therapeutics Services LLC, Horizon Therapeutics Switzerland GmbH, Horizon Therapeutics Treasury DAC, Horizon Therapeutics USA Inc., Hyperion Therapeutics, Hyperion Therapeutics Ireland Holding Limited, Hyperion Therapeutics Ireland Operating Limited, Raptor Pharmaceuticals, River Vision Development Corp., Vidara Therapeutics, and Viela Bio Inc..Read More This page (NASDAQ:HZNP) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsThe World's First "$20 Trillion Drug?"Behind the MarketsI’m afraid WWIII is a very real possibility Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Horizon Therapeutics Public Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
